BRIEF-Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study

Reuters
19 May
BRIEF-Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study

May 19 (Reuters) - Alzamend Neuro Inc ALZN.O:

  • ALZAMEND NEURO ENROLLS FIRST PATIENT IN ITS PHASE II CLINICAL TRIAL OF AL001 “LITHIUM IN BRAIN” STUDY TAKING PLACE AT MASSACHUSETTS GENERAL HOSPITAL

  • ALZAMEND NEURO INC - TOPLINE DATA FOR AL001 EXPECTED BY YEAR END

Source text: ID:nGNX8bLmB2

Further company coverage: ALZN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10